0001104659-26-052107
SEC filingBicycle Therapeutics reported Q1 2026 financial results with $559.5M cash runway into 2030, positive nuzefatide data in EphA2 cancers, Duravelo-2 updates, and strategic reprioritization including 30% workforce cut.
Bicycle Therapeutics' Q1 2026 results reflect a strategic pivot amid clinical progress. Revenue dropped 91% YoY to $0.9M due to terminated collaborations with Genentech and Novartis, driving flat net loss of $60.8M despite R&D expenses falling 17% to $48.9M and G&A down 17% to $17.5M, aided by early workforce adjustments. Cash burn of $68.6M from operations left $559.5M in cash equivalents as of March 31, 2026, down from $628.1M year-end 2025. CEO Kevin Lee highlighted nuzefatide pevedotin's (EphA2 BDC) differentiated profile, with Phase 1/2 data showing 40% ORR (100% in MMAE-naïve EphA2+ mUC patients) combined with nivolumab, no Grade ≥3 TRAEs of interest, supporting Phase 2 initiation in PDAC (first patient dosed April 2026 at 8mg/m² Q2W). AACR data reinforced EphA2 targeting via PDX/CDX models and BIA imaging detecting metastases in 15/18 PDAC patients. Duravelo-2 zelenectide (Nectin-4 BDC) posted 58-62% BICR ORR in mUC with favorable safety, prompting conversion to randomized Phase 2 while deprioritizing internal development amid regulatory feedback. March reprioritization halts Duravelo-3/4 trials, cuts workforce 30%, targets 50% opex reduction, extending runway into 2030—two years beyond prior expectations. ASCO will feature Duravelo-2 dose data, balancing pipeline focus on nuzefatide and BRCs.